<DOC>
	<DOCNO>NCT00978367</DOCNO>
	<brief_summary>The purpose study investigate dosing frequency , wound heal ( re-epithelialisation ) anti-scarring effect one , three five application two concentration intradermal RN1001 healthy male subject .</brief_summary>
	<brief_title>Investigation Safety , Dosing Frequency Anti-Scarring Potential Two Concentrations Intradermal Avotermin ( Juvista )</brief_title>
	<detailed_description>Subjects randomise two cohort , receive either 5 ng avotermin dos 50 ng dos , minimum 21 subject per cohort . Within cohort subject randomise one three dose group ( 7 subject per group ) . Subjects receive four 3 mm punch biopsy , two upper-inner aspect arm . One treatment randomly allocate one biopsy one arm , opposite biopsy arm set receive treatment . The treatment administer two biopsy ( one arm . This allow control possible positional effect heal . Three subject per group receive intradermal avotermin one biopsy arm intradermal placebo biopsy . A different three subject receive intradermal avotermin one biopsy arm standard care biopsy . The final subject per group receive intradermal placebo one biopsies arm standard care biopsy . On day 0 biopsy site mark arm follow local anaesthesia avotermin , placebo nothing inject intradermally allocate site . Subjects dose frequency group 1 ( DFG 1 ) dose ( day 0 ) , subject DFG 2 dose three time ( day 0 , 1 2 ) subject DFG 3 dose five time ( day 0 , 1 , 2 , 3 4 ) . On Day 5 , subject punch biopsy wound one arm re-dosed per Day 0 excise 5 mm surgical ellipse . Subjects DFG2 DFG3 receive re-dosing excise punch biopsy , i.e . three dos DFG2 five dos DFG3 . Subjects return first follow-up day 14 month 2 , 4 6 examine anti-scarring effect . At month 6 scar excise histological examination .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Healthy , nonCaribbean , male subject age 1845 year inclusive Weight 60150 kg BMI within permitted range height use Quetelet 's index ( 1545 kg/m ( square ) ) ( weight ( kg ) /height ( square ) ( ) ) Subjects previous history surgery minor injury develop evidence hypertrophic keloid scar formation Subjects history evidence hypertrophic keloid scar Subjects tattoos previous scar area biopsied Subjects evidence past present clinically significant disease , particularly coagulation disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Avotermin</keyword>
	<keyword>Juvista</keyword>
	<keyword>RN1001</keyword>
	<keyword>TGF beta 3</keyword>
</DOC>